{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T20:08:17Z","timestamp":1776197297584,"version":"3.50.1"},"reference-count":216,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fundo Europeu de Desenvolvimento Regional","award":["UIDB\/4255\/2020"],"award-info":[{"award-number":["UIDB\/4255\/2020"]}]},{"name":"Fundo Europeu de Desenvolvimento Regional","award":["IF\/00092\/2014\/CP1255\/CT0004"],"award-info":[{"award-number":["IF\/00092\/2014\/CP1255\/CT0004"]}]},{"name":"Portuguese funds","award":["UIDB\/4255\/2020"],"award-info":[{"award-number":["UIDB\/4255\/2020"]}]},{"name":"Portuguese funds","award":["IF\/00092\/2014\/CP1255\/CT0004"],"award-info":[{"award-number":["IF\/00092\/2014\/CP1255\/CT0004"]}]},{"name":"FCT and FEDER (European Union)","award":["UIDB\/4255\/2020"],"award-info":[{"award-number":["UIDB\/4255\/2020"]}]},{"name":"FCT and FEDER (European Union)","award":["IF\/00092\/2014\/CP1255\/CT0004"],"award-info":[{"award-number":["IF\/00092\/2014\/CP1255\/CT0004"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Breast cancer remains one of the most prevalent diseases worldwide, primarily affecting women. Its heterogeneous nature poses a significant challenge in the development of effective and targeted treatments. Molecular characterization has enabled breast cancer to be classified into four main subtypes: luminal A, luminal B, HER2-positive, and triple-negative breast cancer, based on hormone receptor expression and HER2 status. A deeper understanding of these molecular markers and their associated signaling pathways, such as MAPK and PI3K\/AKT, is essential for improving prognosis and optimizing treatment strategies. Currently, several therapeutic agents are utilized in neoadjuvant and adjuvant therapies, often in combination with surgical interventions. However, emerging evidence highlights the growing challenge of drug resistance, which significantly limits the efficacy of existing treatments. Addressing this issue may require innovative approaches, including combination therapies and precision medicine strategies, tailored to the molecular profile of each patient. Therefore, a comprehensive understanding of the pathophysiologic mechanisms driving breast cancer progression and resistance is crucial for the development of advanced targeted therapies with greater precision and efficacy. This review aims to explore recent advancements in molecular research related to breast cancer subtypes and provide a critical analysis of current therapeutic approaches within the framework of precision medicine.<\/jats:p>","DOI":"10.3390\/cancers17071102","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T12:18:52Z","timestamp":1742905132000},"page":"1102","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Molecular Subtypes and Mechanisms of Breast Cancer: Precision Medicine Approaches for Targeted Therapies"],"prefix":"10.3390","volume":"17","author":[{"given":"Eduarda","family":"Carvalho","sequence":"first","affiliation":[{"name":"PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}]},{"given":"Sule","family":"Canberk","sequence":"additional","affiliation":[{"name":"PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"RISE-Health, Department of Pathology, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1006-6946","authenticated-orcid":false,"given":"Fernando","family":"Schmitt","sequence":"additional","affiliation":[{"name":"PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"RISE-Health, Department of Pathology, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1283-1042","authenticated-orcid":false,"given":"Nuno","family":"Vale","sequence":"additional","affiliation":[{"name":"PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"RISE-Health, Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"ref_1","unstructured":"(2024, December 08). Breast Cancer. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer."},{"key":"ref_2","unstructured":"(2024, December 08). Breast Cancer Statistics. Available online: https:\/\/www.wcrf.org\/preventing-cancer\/cancer-statistics\/breast-cancer-statistics\/."},{"key":"ref_3","unstructured":"(2025, January 29). Breast Cancer Facts. Available online: https:\/\/www.europadonna.org\/breast-cancer\/."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ogc.2021.11.010","article-title":"Disparities in Breast Cancer","volume":"49","author":"Grabinski","year":"2022","journal-title":"Obstet. Gynecol. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"565","DOI":"10.21147\/j.issn.1000-9604.2023.06.02","article-title":"Breast Cancer: Epidemiology, Risk Factors and Screening","volume":"35","author":"Xu","year":"2023","journal-title":"Chin. J. Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.critrevonc.2007.09.001","article-title":"Impact of Aging on the Biology of Breast Cancer","volume":"66","author":"Benz","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/GRF.0000000000000239","article-title":"Breast Cancer Epidemiology and Risk Factors","volume":"59","author":"Rojas","year":"2016","journal-title":"Clin. Obstet. Gynecol."},{"key":"ref_8","unstructured":"(2025, March 06). European Guidelines on Breast Cancer Screening and Diagnosis. Available online: https:\/\/cancer-screening-and-care.jrc.ec.europa.eu\/en\/ecibc\/european-breast-cancer-guidelines?topic=63&usertype=60&filter_1=80&filter_2=79&updatef2=0."},{"key":"ref_9","unstructured":"(2025, March 06). Screening for Breast Cancer, Available online: https:\/\/www.cdc.gov\/breast-cancer\/screening\/index.html."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e36905","DOI":"10.1097\/MD.0000000000036905","article-title":"Breast Cancer: A Review of Risk Factors and Diagnosis","volume":"103","author":"Obeagu","year":"2024","journal-title":"Medicine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.breast.2022.09.007","article-title":"Mammographic Breast Density and the Risk of Breast Cancer: A Systematic Review and Meta-Analysis","volume":"66","author":"Bodewes","year":"2022","journal-title":"Breast"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Mokhtary, A., Karakatsanis, A., and Valachis, A. (2021). Mammographic Density Changes over Time and Breast Cancer Risk: A Systematic Review and Meta-Analysis. Cancers, 13.","DOI":"10.3390\/cancers13194805"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1007\/s00330-022-08617-6","article-title":"Breast Cancer Screening in Women with Extremely Dense Breasts Recommendations of the European Society of Breast Imaging (EUSOBI)","volume":"32","author":"Mann","year":"2022","journal-title":"Eur. Radiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/jamaoncol.2023.6944","article-title":"MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence Variations","volume":"10","author":"Lubinski","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10549-006-9446-y","article-title":"Breast Cancer Risk Factors and Second Primary Malignancies among Women with Breast Cancer","volume":"105","author":"Newcomb","year":"2007","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10549-017-4325-2","article-title":"Family History and Risk of Breast Cancer: An Analysis Accounting for Family Structure","volume":"165","author":"Brewer","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Liu, L., Hao, X., Song, Z., Zhi, X., Zhang, S., and Zhang, J. (2021). Correlation between Family History and Characteristics of Breast Cancer. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-85899-8"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/TACG.S13139","article-title":"The Genetics of Breast Cancer: Risk Factors for Disease","volume":"4","author":"Collins","year":"2011","journal-title":"Appl. Clin. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e4975","DOI":"10.1097\/MD.0000000000004975","article-title":"Effect of BRCA Germline Mutations on Breast Cancer Prognosis: A Systematic Review and Meta-Analysis","volume":"95","author":"Baretta","year":"2016","journal-title":"Medicine"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.7150\/jca.30410","article-title":"BRCA Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance","volume":"10","author":"Gorodetska","year":"2019","journal-title":"J. Cancer"},{"key":"ref_21","first-page":"492","article-title":"Risk Factors, Genetic Mutations and Prevention of Breast Cancer","volume":"14","author":"Naeem","year":"2019","journal-title":"Int. J. Biosci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S1470-2045(12)70425-4","article-title":"Menarche, Menopause, and Breast Cancer Risk: Individual Participant Meta-Analysis, Including 118\u2008964 Women with Breast Cancer from 117 Epidemiological Studies","volume":"13","author":"Hamajima","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.steroids.2012.11.001","article-title":"Estrogen Receptor-Dependent and Independent Mechanisms of Breast Cancer Carcinogenesis","volume":"78","author":"Yue","year":"2013","journal-title":"Steroids"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/bs.pmbts.2017.07.006","article-title":"Pregnancy and Breast Cancer","volume":"151","author":"Subramani","year":"2017","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.1002\/cam4.5288","article-title":"Breastfeeding Reduces the Risk of Breast Cancer: A Call for Action in High-income Countries with Low Rates of Breastfeeding","volume":"12","author":"Stordal","year":"2022","journal-title":"Cancer Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/978-3-030-41596-9_27","article-title":"Pregnancy and Lactation: Risk or Protective Factors for Breast Cancer?","volume":"1252","author":"Peccatori","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"101577","DOI":"10.1016\/j.beem.2021.101577","article-title":"Menopausal Hormone Therapy and Breast Cancer Risk","volume":"35","author":"Rozenberg","year":"2021","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/ijgo.15461","article-title":"Relationship between Menopausal Hormone Therapy and Breast Cancer: A Nationwide Population-Based Cohort Study","volume":"166","author":"Yuk","year":"2024","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Kanadys, W., Bara\u0144ska, A., Malm, M., B\u0142aszczuk, A., Polz-Dacewicz, M., Janiszewska, M., and J\u0119drych, M. (2021). Use of Oral Contraceptives as a Potential Risk Factor for Breast Cancer: A Systematic Review and Meta-Analysis of Case-Control Studies up to 2010. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18094638"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3332\/ecancer.2022.1416","article-title":"Review of the Literature on Combined Oral Contraceptives and Cancer","volume":"16","author":"Kamani","year":"2022","journal-title":"Ecancermedicalscience"},{"key":"ref_31","unstructured":"(2025, March 06). Obesity. Available online: https:\/\/www.who.int\/health-topics\/obesity#tab=tab_1."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Dehesh, T., Fadaghi, S., Seyedi, M., Abolhadi, E., Ilaghi, M., Shams, P., Ajam, F., Mosleh-Shirazi, M.A., and Dehesh, P. (2023). The Relation between Obesity and Breast Cancer Risk in Women by Considering Menstruation Status and Geographical Variations: A Systematic Review and Meta-Analysis. BMC Womens Health, 23.","DOI":"10.1186\/s12905-023-02543-5"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast Cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_34","first-page":"69","article-title":"Alcohol and Breast Cancer","volume":"75","author":"Budziszewska","year":"2022","journal-title":"Pharmacol. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10549-020-05679-2","article-title":"Exploring the Effects of Lifestyle on Breast Cancer Risk, Age at Diagnosis, and Survival: The EBBA-Life Study","volume":"182","author":"Frydenberg","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_36","unstructured":"National Cancer Policy Forum, Board on Health Care Services, and Institute of Medicine (2013). Tobacco use and cancer. Reducing Tobacco-Related Cancer Incidence and Mortality: Workshop Summary, National Academies Press (US)."},{"key":"ref_37","first-page":"157","article-title":"Smoking History and Breast Cancer Risk by Pathological Subtype: MCC-Spain Study","volume":"21","author":"Amiano","year":"2023","journal-title":"Tob. Induc. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"He, Y., Si, Y., Li, X., Hong, J., Yu, C., and He, N. (2022). The Relationship between Tobacco and Breast Cancer Incidence: A Systematic Review and Meta-Analysis of Observational Studies. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.961970"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1007\/s10552-013-0298-6","article-title":"A Prospective Study of Smoking and Breast Cancer Risk among African American Women","volume":"24","author":"Rosenberg","year":"2013","journal-title":"Cancer Causes Control"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.7150\/ijbs.21635","article-title":"Risk Factors and Preventions of Breast Cancer","volume":"13","author":"Sun","year":"2017","journal-title":"Int. J. Biol. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/bjsports-2021-105132","article-title":"Physical Activity, Sedentary Time and Breast Cancer Risk: A Mendelian Randomization Study","volume":"56","author":"Lewis","year":"2022","journal-title":"Br. J. Sports Med."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Boraka, \u00d6., Klintman, M., and Rosendahl, A.H. (2022). Physical Activity and Long-Term Risk of Breast Cancer, Associations with Time in Life and Body Composition in the Prospective Malm\u00f6 Diet and Cancer Study. Cancers, 14.","DOI":"10.3390\/cancers14081960"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/oem.2009.053512","article-title":"Considerations of Circadian Impact for Defining \u201cshift Work\u201d in Cancer Studies: IARC Working Group Report","volume":"68","author":"Stevens","year":"2011","journal-title":"Occup. Environ. Med."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Salgado, J., Fagundo-Rivera, J., Ortega-Moreno, M., Allande-Cuss\u00f3, R., Ayuso-Murillo, D., and Ruiz-Frutos, C. (2021). Night Work and Breast Cancer Risk in Nurses: Multifactorial Risk Analysis. Cancers, 13.","DOI":"10.3390\/cancers13061470"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Szkiela, M., Kuside\u0142, E., Makowiec-Dabrowska, T., and Kaleta, D. (2021). How the Intensity of Night Shift Work Affects Breast Cancer Risk. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18094570"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jncc.2024.07.004","article-title":"Night Shift Work and Breast Cancer Risk\u20142023 Update of Epidemiologic Evidence","volume":"5","author":"Hansen","year":"2025","journal-title":"J. Natl. Cancer Cent."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1600-079X.2004.00207.x","article-title":"Melatonin\u2013Estrogen Interactions in Breast Cancer","volume":"38","author":"Cos","year":"2005","journal-title":"J. Pineal Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.critrevonc.2017.12.018","article-title":"Melatonin and Breast Cancer: Evidences from Preclinical and Human Studies","volume":"122","author":"Kubatka","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1615\/JEnvironPatholToxicolOncol.2022041294","article-title":"Melatonin: A Potential Antineoplastic Agent in Breast Cancer","volume":"41","author":"Samanta","year":"2022","journal-title":"J. Environ. Pathol. Toxicol. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s11325-021-02523-9","article-title":"Night-Shift Work, Breast Cancer Incidence, and All-Cause Mortality: An Updated Meta-Analysis of Prospective Cohort Studies","volume":"26","author":"Wei","year":"2022","journal-title":"Sleep Breath."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Barletta, J.A. (2014). Surgical Pathology of Carcinomas. Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms, Elsevier.","DOI":"10.1016\/B978-0-12-386456-7.06904-5"},{"key":"ref_52","unstructured":"Tomlinson-Hansen, S.E., Khan, M., and Cassaro, S. (2023). Breast Ductal Carcinoma in Situ. StatPearls, StatPearls Publishing."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41379-020-00689-3","article-title":"Lobular Carcinoma in Situ: Diagnostic Criteria and Molecular Correlates","volume":"34","author":"Sokolova","year":"2021","journal-title":"Mod. Pathol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Sahin, A., and Zhang, H. (2014). Invasive Breast Carcinoma. Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms, Elsevier.","DOI":"10.1016\/B978-0-12-386456-7.03204-4"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4137\/CPath.S31563","article-title":"Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance","volume":"8","author":"Makki","year":"2015","journal-title":"Clin. Med. Insights Pathol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13058-020-01384-6","article-title":"Invasive Lobular Carcinoma of the Breast: The Increasing Importance of This Special Subtype","volume":"23","author":"Kalinowski","year":"2021","journal-title":"Breast Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11912-019-0842-y","article-title":"Inflammatory Breast Cancer: A Separate Entity","volume":"21","author":"Rosenbluth","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4103\/2231-4040.72251","article-title":"Various Types and Management of Breast Cancer: An Overview","volume":"1","author":"Sharma","year":"2010","journal-title":"J. Adv. Pharm. Technol. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e20200024","DOI":"10.29289\/25945394202020200024","article-title":"Histological and Molecular Classification of Breast Cancer: What Do We Know?","volume":"30","author":"Otoni","year":"2020","journal-title":"Mastology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5858\/arpa.2022-0070-RA","article-title":"Molecular Classification of Breast Cancer: Relevance and Challenges","volume":"147","author":"Zhang","year":"2023","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cpet.2023.04.002","article-title":"Molecular Classification of Breast Cancer","volume":"18","author":"Roy","year":"2023","journal-title":"PET Clin."},{"key":"ref_62","unstructured":"(2025, March 07). M\u00e9todos de Tratamento\u2014Cancro da Mama. Available online: https:\/\/www.ligacontracancro.pt\/cancro-da-mama-metodos-de-tratamento\/."},{"key":"ref_63","unstructured":"(2025, March 07). Treatment for Breast Cancer. Available online: https:\/\/www.cancerresearchuk.org\/about-cancer\/breast-cancer\/treatment."},{"key":"ref_64","unstructured":"(2025, March 07). Treatment Options for Breast Cancer. Available online: https:\/\/www.cancer.org\/cancer\/types\/breast-cancer\/treatment.html."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Fumagalli, C., and Barberis, M. (2021). Breast Cancer Heterogeneity. Diagnostics, 11.","DOI":"10.3390\/diagnostics11091555"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Gawin, M., Kurczyk, A., Niemiec, J., Stanek-Widera, A., Grela-Wojewoda, A., Adamczyk, A., Biskup-Fru\u017cy\u0144ska, M., Pola\u0144ska, J., and Wid\u0142ak, P. (2021). Intra-Tumor Heterogeneity Revealed by Mass Spectrometry Imaging Is Associated with the Prognosis of Breast Cancer. Cancers, 13.","DOI":"10.3390\/cancers13174349"},{"key":"ref_67","first-page":"81","article-title":"Tumour Heterogeneity and Resistance to Cancer Therapies","volume":"15","author":"Shaw","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Proietto, M., Crippa, M., Damiani, C., Pasquale, V., Sacco, E., Vanoni, M., and Gilardi, M. (2023). Tumor Heterogeneity: Preclinical Models, Emerging Technologies, and Future Applications. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1164535"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1200\/EDBK_158808","article-title":"Tumor Heterogeneity and Therapeutic Resistance","volume":"36","author":"Lovly","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_70","first-page":"2920","article-title":"Breast Cancer: Molecular Mechanisms of Underlying Resistance and Therapeutic Approaches","volume":"12","author":"Tufail","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Kinnel, B., Singh, S.K., Oprea-Ilies, G., and Singh, R. (2023). Targeted Therapy and Mechanisms of Drug Resistance in Breast Cancer. Cancers, 15.","DOI":"10.3390\/cancers15041320"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"120","DOI":"10.5306\/wjco.v8.i2.120","article-title":"Targeted Therapies in Breast Cancer: New Challenges to Fight against Resistance","volume":"8","author":"Masoud","year":"2017","journal-title":"World J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3322\/caac.21689","article-title":"Radiation Therapy-Associated Toxicity: Etiology, Management, and Prevention","volume":"71","author":"Wang","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_74","first-page":"100119","article-title":"An Update on Breast Cancer Chemotherapy-Associated Toxicity and Their Management Approaches","volume":"9","author":"Langeh","year":"2023","journal-title":"Health Sci. Rev."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1200\/EDBK_279465","article-title":"What\u2019s the Price? Toxicities of Targeted Therapies in Breast Cancer Care","volume":"40","author":"Anders","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Mark, C., Lee, J.S., Cui, X., and Yuan, Y. (2023). Antibody\u2013Drug Conjugates in Breast Cancer: Current Status and Future Directions. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241813726"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cac2.12387","article-title":"Resistance to Antibody-drug Conjugates in Breast Cancer: Mechanisms and Solutions","volume":"43","author":"Chen","year":"2022","journal-title":"Cancer Commun."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e172156","DOI":"10.1172\/JCI172156","article-title":"Antibody-Drug Conjugates in Breast Cancer: Overcoming Resistance and Boosting Immune Response","volume":"133","author":"Chang","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.gendis.2020.12.005","article-title":"Role of Hormone Receptors and HER2 as Prospective Molecular Markers for Breast Cancer: An Update","volume":"9","author":"Mohanty","year":"2022","journal-title":"Genes Dis."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Clusan, L., Ferri\u00e8re, F., Flouriot, G., and Pakdel, F. (2023). A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076834"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Mayrovitz, H.N. (2022). Subtypes of Breast Cancer. Breast Cancer, Exon Publications.","DOI":"10.36255\/exon-publications-breast-cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-Low Breast Cancer: Pathological and Clinical Landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-Negative Breast Cancer Molecular Subtyping and Treatment Progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO\/CAP Guideline Update","volume":"38","author":"Allison","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.ctrv.2011.11.005","article-title":"Molecular Biology in Breast Cancer: Intrinsic Subtypes and Signaling Pathways","volume":"38","author":"Eroles","year":"2012","journal-title":"Cancer Treat. Rev."},{"key":"ref_86","unstructured":"(2025, March 12). Breast Cancer\u2014Molecular Subtypes. Available online: https:\/\/www.pathologyoutlines.com\/topic\/breastmolecularsubtypes.html."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"113371","DOI":"10.1016\/j.ejca.2023.113371","article-title":"Characterisation of Luminal and Triple-Negative Breast Cancer with HER2 Low Protein Expression","volume":"195","author":"Atallah","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update","volume":"41","author":"Wolff","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"10402","DOI":"10.1038\/s41467-024-54621-3","article-title":"Identification of HER2-Positive Breast Cancer Molecular Subtypes with Potential Clinical Implications in the ALTTO Clinical Trial","volume":"15","author":"Rediti","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40246-023-00493-5","article-title":"Genetic Mutations in HER2-Positive Breast Cancer: Possible Association with Response to Trastuzumab Therapy","volume":"17","author":"Zakaria","year":"2023","journal-title":"Hum. Genom."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"BMT71","DOI":"10.2217\/bmt-2023-0017","article-title":"The Characteristics of HER2 Low-Expressing Breast Cancer: A China Single-Center Real-World Data Analysis","volume":"12","author":"Chen","year":"2023","journal-title":"Breast Cancer Manag."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2853007","DOI":"10.1155\/2024\/2853007","article-title":"Insights Into the Emerging Entity of HER2-Low Breast Cancer","volume":"2024","author":"Diab","year":"2024","journal-title":"Int. J. Breast Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"421114","DOI":"10.1200\/JCO.2024.42.16_suppl.1114","article-title":"Molecular and Immunological Characterization of Androgen Receptor Expression in Different Breast Cancer Subtypes","volume":"42","author":"Jayachandran","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","article-title":"Pathogenesis of Triple-Negative Breast Cancer","volume":"17","author":"Derakhshan","year":"2022","journal-title":"Annu. Rev. Pathol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","article-title":"Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies","volume":"35","author":"Jiang","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1038\/s41467-020-17249-7","article-title":"Comprehensive Characterization of Claudin-Low Breast Tumors Reflects the Impact of the Cell-of-Origin on Cancer Evolution","volume":"11","author":"Pommier","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Pan, C., Xu, A., Ma, X., Yao, Y., Zhao, Y., Wang, C., and Chen, C. (2023). Research Progress of Claudin-Low Breast Cancer. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1226118"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"9258396","DOI":"10.1155\/2020\/9258396","article-title":"Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K\/Akt\/MTOR","volume":"2020","author":"Ortega","year":"2020","journal-title":"J. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Miziak, P., Baran, M., B\u0142aszczak, E., Przybyszewska-Podstawka, A., Ka\u0142afut, J., Smok-Kalwat, J., Dmoszy\u0144ska-Graniczka, M., Kie\u0142bus, M., and Stepulak, A. (2023). Estrogen Receptor Signaling in Breast Cancer. Cancers, 15.","DOI":"10.3390\/cancers15194689"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.cmet.2020.05.008","article-title":"The Major Pre- and Postmenopausal Estrogens Play Opposing Roles in Obesity-Driven Mammary Inflammation and Breast Cancer Development","volume":"31","author":"Qureshi","year":"2020","journal-title":"Cell Metab."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/bs.apcsb.2019.01.001","article-title":"Estrogen Receptor Signaling Mechanisms","volume":"116","author":"Fuentes","year":"2019","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10911-021-09497-0","article-title":"Estetrol and Mammary Gland: Friends or Foes?","volume":"26","author":"Gallez","year":"2021","journal-title":"J. Mammary Gland. Biol. Neoplasia"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.2147\/OTT.S236532","article-title":"ER\u03b1, A Key Target for Cancer Therapy: A Review","volume":"13","author":"Liu","year":"2020","journal-title":"Onco Targets Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1210\/me.2004-0486","article-title":"Mechanisms of Estrogen Receptor Signaling: Convergence of Genomic and Nongenomic Actions on Target Genes","volume":"19","year":"2005","journal-title":"Mol. Endocrinol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"385","DOI":"10.37349\/etat.2021.00052","article-title":"Role of Estrogen Receptor Coregulators in Endocrine Resistant Breast Cancer","volume":"2","author":"Altwegg","year":"2021","journal-title":"Explor. Target. Antitumor Ther."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Mal, R., Magner, A., David, J., Datta, J., Vallabhaneni, M., Kassem, M., Manouchehri, J., Willingham, N., Stover, D., and Vandeusen, J. (2020). Estrogen Receptor Beta (ER\u03b2): A Ligand Activated Tumor Suppressor. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.587386"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Miricescu, D., Totan, A., Stanescu-Spinu, I.I., Badoiu, S.C., Stefani, C., and Greabu, M. (2020). PI3K\/AKT\/MTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010173"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3390\/receptors3020010","article-title":"Estrogen Signals through ER\u03b2 in Breast Cancer; What We Have Learned since the Discovery of the Receptor","volume":"3","author":"Nagandla","year":"2024","journal-title":"Receptors"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1158\/0008-5472.CAN-03-2446","article-title":"Estrogen Receptor \u03b2 Inhibits Human Breast Cancer Cell Proliferation and Tumor Formation by Causing a G2 Cell Cycle Arrest","volume":"64","author":"Paruthiyil","year":"2004","journal-title":"Cancer Res."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Zhou, Y., and Liu, X. (2020). The Role of Estrogen Receptor Beta in Breast Cancer. Biomark. Res., 8.","DOI":"10.1186\/s40364-020-00223-2"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4048\/jbc.2022.25.e9","article-title":"Estrogen Receptor \u03b2 Expression and Its Clinical Implication in Breast Cancers: Favorable or Unfavorable?","volume":"25","author":"Choi","year":"2022","journal-title":"J. Breast Cancer"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2147\/DDDT.S336643","article-title":"The Role of Progesterone Receptors in Breast Cancer","volume":"16","author":"Li","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1210\/endrev\/bnz001","article-title":"Progesterone and Breast Cancer","volume":"41","author":"Trabert","year":"2020","journal-title":"Endocr. Rev."},{"key":"ref_114","first-page":"5214","article-title":"New Insights into the Functions of Progesterone Receptor (PR) Isoforms and Progesterone Signaling","volume":"11","author":"Azeez","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e38508","DOI":"10.1097\/MD.0000000000038508","article-title":"HER2\/PI3K\/AKT Pathway in HER2-Positive Breast Cancer A Review","volume":"103","author":"Pan","year":"2024","journal-title":"Medicine"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5858\/2010-0454-RAR.1","article-title":"HER 2: Biology, Detection, and Clinical Implications","volume":"135","author":"Gutierrez","year":"2011","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Zhong, H., Zhou, Z., Wang, H., Wang, R., Shen, K., Huang, R., Zhong, H., Zhou, Z., Wang, H., and Wang, R. (2024). The Biological Roles and Clinical Applications of the PI3K\/AKT Pathway in Targeted Therapy Resistance in HER2-Positive Breast Cancer: A Comprehensive Review. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252413376"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2147\/BCTT.S366122","article-title":"HER2-Low Breast Cancer: Current Landscape and Future Prospects","volume":"15","author":"Shirman","year":"2023","journal-title":"Breast Cancer Targets Ther."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/ajcp\/aqab117","article-title":"HER2-Low Breast Cancers: New Opportunities and Challenges","volume":"157","author":"Zhang","year":"2022","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"5112","DOI":"10.1038\/s41467-023-40715-x","article-title":"Molecular Features and Clinical Implications of the Heterogeneity in Chinese Patients with HER2-Low Breast Cancer","volume":"14","author":"Dai","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10911-014-9329-5","article-title":"The HER2 Signaling Network in Breast Cancer\u2014Like a Spider in Its Web","volume":"19","author":"Dittrich","year":"2014","journal-title":"J. Mammary Gland. Biol. Neoplasia"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK Pathway for Cancer Therapy: From Mechanism to Clinical Studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Rocca, A., Braga, L., Volpe, M.C., Maiocchi, S., and Generali, D. (2022). The Predictive and Prognostic Role of RAS\u2013RAF\u2013MEK\u2013ERK Pathway Alterations in Breast Cancer: Revision of the Literature and Comparison with the Analysis of Cancer Genomic Datasets. Cancers, 14.","DOI":"10.3390\/cancers14215306"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Karim, A.M., Eun Kwon, J., Ali, T., Jang, J., Ullah, I., Lee, Y.G., Park, D.W., Park, J., Jeang, J.W., and Kang, S.C. (2023). Triple-Negative Breast Cancer: Epidemiology, Molecular Mechanisms, and Modern Vaccine-Based Treatment Strategies. Biochem. Pharmacol., 212.","DOI":"10.1016\/j.bcp.2023.115545"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Choi, E., Mun, G.I., Lee, J., Lee, H., Cho, J., and Lee, Y.S. (2023). BRCA1 Deficiency in Triple-Negative Breast Cancer: Protein Stability as a Basis for Therapy. Biomed. Pharmacother., 158.","DOI":"10.1016\/j.biopha.2022.114090"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00404-015-3859-y","article-title":"An Overview of Triple-Negative Breast Cancer","volume":"293","author":"Kumar","year":"2016","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e31705","DOI":"10.1097\/MD.0000000000031705","article-title":"BRCA2 Gene Mutation in Cancer","volume":"101","author":"Xie","year":"2022","journal-title":"Medicine"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Fu, X., Tan, W., Song, Q., Pei, H., and Li, J. (2022). BRCA1 and Breast Cancer: Molecular Mechanisms and Therapeutic Strategies. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.813457"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41523-019-0110-1","article-title":"Therapeutic Targeting of BRCA1 and TP53 Mutant Breast Cancer through Mutant P53 Reactivation","volume":"5","author":"Na","year":"2019","journal-title":"NPJ Breast Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Arimura, A., Sakai, K., Kaneshiro, K., Morisaki, T., Hayashi, S., Mizoguchi, K., Yamada, M., Kai, M., Ono, M., and Nishio, K. (2024). TP53 and\/or BRCA1 Mutations Based on CtDNA Analysis as Prognostic Biomarkers for Primary Triple-Negative Breast Cancer. Cancers, 16.","DOI":"10.3390\/cancers16061184"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1007\/s12282-024-01603-4","article-title":"Neoadjuvant Talazoparib in Patients with Germline BRCA1\/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Exploration of Tumor BRCA Mutational Status","volume":"31","author":"Telli","year":"2024","journal-title":"Breast Cancer"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"e216744","DOI":"10.1001\/jamaoncol.2021.6744","article-title":"Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes","volume":"8","author":"Mavaddat","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"102140","DOI":"10.1016\/j.tranon.2024.102140","article-title":"The PIK3CA Gene and Its Pivotal Role in Tumor Tropism of Triple-Negative Breast Cancer","volume":"50","author":"Mallick","year":"2024","journal-title":"Transl. Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.annonc.2019.11.006","article-title":"Outcome and Molecular Landscape of Patients with PIK3CA-Mutated Metastatic Breast Cancer","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10549-022-06637-w","article-title":"PIK3CA-Mutations in Breast Cancer","volume":"196","author":"Reinhardt","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1001\/jamaoncol.2016.1897","article-title":"Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-Analysis","volume":"2","author":"Spring","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.soncn.2015.02.002","article-title":"Endocrine Therapy in Breast Cancer: The Neoadjuvant, Adjuvant, and Metastatic Approach","volume":"31","author":"Reinbolt","year":"2015","journal-title":"Semin. Oncol. Nurs."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"102375","DOI":"10.1016\/j.ctrv.2022.102375","article-title":"Adjuvant and Neoadjuvant Breast Cancer Treatments: A Systematic Review of Their Effects on Mortality","volume":"105","author":"Kerr","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Barchiesi, G., Mazzotta, M., Krasniqi, E., Pizzuti, L., Marinelli, D., Capomolla, E., Sergi, D., Amodio, A., Natoli, C., and Gamucci, T. (2020). Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21103528"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3892\/mmr.2024.13304","article-title":"Crosstalk of Methylation and Tamoxifen in Breast Cancer (Review)","volume":"30","author":"Shen","year":"2024","journal-title":"Mol. Med. Rep."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"13738","DOI":"10.18632\/aging.205260","article-title":"Involvement of RFC3 in Tamoxifen Resistance in ER-Positive Breast Cancer through the Cell Cycle","volume":"15","author":"Zhu","year":"2023","journal-title":"Aging"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Generali, D., Berardi, R., Caruso, M., Cazzaniga, M., Garrone, O., Minchella, I., Paris, I., Pinto, C., and De Placido, S. (2023). Aromatase Inhibitors: The Journey from the State of the Art to Clinical Open Questions. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1249160"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e137571","DOI":"10.1172\/jci.insight.137571","article-title":"Pharmacogenomics of Aromatase Inhibitors in Postmenopausal Breast Cancer and Additional Mechanisms of Anastrozole Action","volume":"5","author":"Cairns","year":"2020","journal-title":"JCI Insight"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"e2000081","DOI":"10.1002\/ardp.202000081","article-title":"Aromatase Inhibitors: Role in Postmenopausal Breast Cancer","volume":"353","author":"Kharb","year":"2020","journal-title":"Arch. Pharm."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","article-title":"Aromatase Inhibitors versus Tamoxifen in Early Breast Cancer: Patient-Level Meta-Analysis of the Randomised Trials","volume":"386","author":"Bradley","year":"2015","journal-title":"Lancet"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1470-2045(21)00758-0","article-title":"Aromatase Inhibitors versus Tamoxifen in Premenopausal Women with Oestrogen Receptor-Positive Early-Stage Breast Cancer Treated with Ovarian Suppression: A Patient-Level Meta-Analysis of 7030 Women from Four Randomised Trials","volume":"23","author":"Bradley","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s11864-023-01137-5","article-title":"Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer","volume":"24","author":"Senkus","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-Positive Breast Cancer: Advances and Future Directions","volume":"22","author":"Swain","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.21037\/tcr.2018.09.07","article-title":"What Is the Role of HER2-Specific Antibody Immunity in Patients with HER2-Positive Early Breast Cancer Receiving Chemotherapy plus Trastuzumab?","volume":"7","author":"Mehanna","year":"2018","journal-title":"Transl. Cancer Res."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Maadi, H., and Wang, Z. (2022). A Novel Mechanism Underlying the Inhibitory Effects of Trastuzumab on the Growth of HER2-Positive Breast Cancer Cells. Cells, 11.","DOI":"10.3390\/cells11244093"},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Liu, X., Fang, Y., Li, Y., Li, Y., Qi, L., and Wang, X. (2022). Pertuzumab Combined with Trastuzumab Compared to Trastuzumab in the Treatment of HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.894861"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"e155636","DOI":"10.1172\/jci.insight.155636","article-title":"Trastuzumab\/Pertuzumab Combination Therapy Stimulates Antitumor Responses through Complement-Dependent Cytotoxicity and Phagocytosis","volume":"7","author":"Tsao","year":"2022","journal-title":"JCI Insight"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer","volume":"377","author":"Procter","year":"2017","journal-title":"N. Eng. J. Med."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1001\/jamaoncol.2023.2909","article-title":"Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial","volume":"9","author":"Huober","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12957-024-03365-x","article-title":"Neoadjuvant Pertuzumab plus Trastuzumab in Combination with Chemotherapy for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer: A Real-World Retrospective Single-Institutional Study in China","volume":"22","author":"Peng","year":"2024","journal-title":"World J. Surg. Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1007\/s12094-024-03440-5","article-title":"Real-World Experience with Pertuzumab and Trastuzumab Combined with Chemotherapy in Neoadjuvant Treatment for Patients with Early-Stage HER2-Positive Breast Cancer: The NEOPERSUR Study","volume":"26","author":"Jurado","year":"2024","journal-title":"Clin. Transl. Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/bcr3621","article-title":"Trastuzumab Emtansine: Mechanisms of Action and Drug Resistance","volume":"16","author":"Barok","year":"2014","journal-title":"Breast Cancer Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"104355","DOI":"10.1016\/j.critrevonc.2024.104355","article-title":"Trastuzumab Deruxtecan in Breast Cancer","volume":"198","author":"Pandiella","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results from DESTINY-Breast03, a Randomised, Open-Label, Phase 3 Trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1111\/cas.16234","article-title":"Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Asian Patients with HER2-positive Metastatic Breast Cancer","volume":"115","author":"Iwata","year":"2024","journal-title":"Cancer Sci."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Sarno, F., Dell\u2019aversana, C., Cappetta, D., Megchelenbrink, W.L., Obidiro, O., Battogtokh, G., and Akala, E.O. (2023). Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15071796"},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"van den Ende, N.S., Nguyen, A.H., Jager, A., Kok, M., Debets, R., and van Deurzen, C.H.M. (2023). Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032969"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(23)00285-4","article-title":"Anthracycline-Containing and Taxane-Containing Chemotherapy for Early-Stage Operable Breast Cancer: A Patient-Level Meta-Analysis of 100\u2008000 Women from 86 Randomised Trials","volume":"401","author":"Braybrooke","year":"2023","journal-title":"Lancet"},{"key":"ref_164","first-page":"CD014805","article-title":"Platinum-Based Chemotherapy for Early Triple-Negative Breast Cancer","volume":"9","author":"Mason","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/jama.2020.23370","article-title":"Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial","volume":"325","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/cam4.1954","article-title":"Radiotherapy after Surgery Has Significant Survival Benefits for Patients with Triple-negative Breast Cancer","volume":"8","author":"Yao","year":"2019","journal-title":"Cancer Med."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-023-01850-7","article-title":"Advances in Immunotherapy for Triple-Negative Breast Cancer","volume":"22","author":"Liu","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus Nab-Paclitaxel as First-Line Treatment for Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer (IMpassion130): Updated Efficacy Results from a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/annonc\/mdy518","article-title":"Pembrolizumab Monotherapy for Previously Untreated, PD-L1-Positive, Metastatic Triple-Negative Breast Cancer: Cohort B of the Phase II KEYNOTE-086 Study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_170","first-page":"e071674","article-title":"Advances in Systemic Therapies for Triple Negative Breast Cancer","volume":"381","author":"Goetz","year":"2023","journal-title":"BMJ"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","article-title":"Recent Advances in Therapeutic Strategies for Triple-Negative Breast Cancer","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13045-023-01497-3","article-title":"Recent Advances in Targeted Strategies for Triple-Negative Breast Cancer","volume":"16","author":"Zhu","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-022-00363-1","article-title":"Breast Cancer Heterogeneity and Its Implication in Personalized Precision Therapy","volume":"12","author":"Guo","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/s41467-021-22801-0","article-title":"Single-Cell Profiling of Tumor Heterogeneity and the Microenvironment in Advanced Non-Small Cell Lung Cancer","volume":"12","author":"Wu","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/cac2.12078","article-title":"Single-cell RNA Sequencing in Breast Cancer: Understanding Tumor Heterogeneity and Paving Roads to Individualized Therapy","volume":"40","author":"Ding","year":"2020","journal-title":"Cancer Commun."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.semcancer.2019.08.012","article-title":"Metastatic Heterogeneity of Breast Cancer: Molecular Mechanism and Potential Therapeutic Targets","volume":"60","author":"Liang","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12943-024-01990-4","article-title":"Modulation of the Tumor Microenvironment and Mechanism of Immunotherapy-Based Drug Resistance in Breast Cancer","volume":"23","author":"Kundu","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.cell.2018.05.060","article-title":"Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment","volume":"174","author":"Azizi","year":"2019","journal-title":"Cell"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.ccell.2021.09.010","article-title":"Single-Cell Analyses Reveal Key Immune Cell Subsets Associated with Response to PD-L1 Blockade in Triple-Negative Breast Cancer","volume":"39","author":"Zhang","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"599586","DOI":"10.3389\/fendo.2021.599586","article-title":"Molecular Mechanisms of Endocrine Resistance in Estrogen-Positive Breast Cancer","volume":"12","author":"Belachew","year":"2021","journal-title":"Front Endocrinol."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Yao, J., Deng, K., Huang, J., Zeng, R., and Zuo, J. (2020). Progress in the Understanding of the Mechanism of Tamoxifen Resistance in Breast Cancer. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.592912"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s00109-021-02136-5","article-title":"Endocrine Resistance in Breast Cancer: From Molecular Mechanisms to Therapeutic Strategies","volume":"99","author":"Saatci","year":"2021","journal-title":"J. Mol. Med."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.4155\/fmc.15.93","article-title":"Endocrine Therapy Resistance in Breast Cancer: Current Status, Possible Mechanisms and Overcoming Strategies","volume":"7","author":"Fan","year":"2015","journal-title":"Future Med. Chem."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Bos, M.K., Deger, T., Sleijfer, S., Martens, J.W.M., and Wilting, S.M. (2022). ESR1 Methylation Measured in Cell-Free DNA to Evaluate Endocrine Resistance in Metastatic Breast Cancer Patients. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23105631"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10585-018-9935-5","article-title":"ESR1-Promoter-Methylation Status in Primary Breast Cancer and Its Corresponding Metastases","volume":"35","author":"Kirn","year":"2018","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13058-021-01462-3","article-title":"ESR1 Mutation as an Emerging Clinical Biomarker in Metastatic Hormone Receptor-Positive Breast Cancer","volume":"23","author":"Brett","year":"2021","journal-title":"Breast Cancer Res."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.annonc.2024.09.010","article-title":"Acquired Gene Alterations in Patients Treated with Ribociclib plus Endocrine Therapy or Endocrine Therapy Alone Using Baseline and End-of-Treatment Circulating Tumor DNA Samples in the MONALEESA-2, -3, and -7 Trials","volume":"36","author":"Solovieff","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Raheem, F., Karikalan, S.A., Batalini, F., El Masry, A., and Mina, L. (2023). Metastatic ER+ Breast Cancer: Mechanisms of Resistance and Future Therapeutic Approaches. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242216198"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/1078-0432.CCR-21-3276","article-title":"Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant","volume":"28","author":"Tolaney","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Wu, X., Yang, H., Yu, X., and Qin, J.J. (2022). Drug-Resistant HER2-Positive Breast Cancer: Molecular Mechanisms and Overcoming Strategies. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1012552"},{"key":"ref_191","doi-asserted-by":"crossref","unstructured":"Nami, B., Ghanaeian, A., and Wang, Z. (2020). Epigenetic Downregulation of HER2 during EMT Leads to Tumor Resistance to HER2-Targeted Therapies in Breast Cancer. bioRxiv, 1\u201338.","DOI":"10.1101\/2020.03.24.006379"},{"key":"ref_192","first-page":"382","article-title":"The Role of P95HER2 in Trastuzumab Resistance in Breast Cancer","volume":"21","author":"Eliyatkin","year":"2016","journal-title":"J. BUON"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12943-023-01716-y","article-title":"CMTM6 Overexpression Confers Trastuzumab Resistance in HER2-Positive Breast Cancer","volume":"22","author":"Xing","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Zimmerman, B.S., and Esteva, F.J. (2024). Next-Generation HER2-Targeted Antibody\u2013Drug Conjugates in Breast Cancer. Cancers, 16.","DOI":"10.3390\/cancers16040800"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","article-title":"Mechanisms of Resistance to Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer","volume":"122","author":"Hunter","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00280-020-04222-w","article-title":"Tumor Microenvironment Promotes Breast Cancer Chemoresistance","volume":"87","author":"Mehraj","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41420-023-01306-3","article-title":"Cancer-Associated Fibroblasts Induce Growth and Radioresistance of Breast Cancer Cells through Paracrine IL-6","volume":"9","author":"Guo","year":"2023","journal-title":"Cell Death Discov."},{"key":"ref_198","doi-asserted-by":"crossref","unstructured":"Xiao, M., He, J., Yin, L., Chen, X., Zu, X., and Shen, Y. (2021). Tumor-Associated Macrophages: Critical Players in Drug Resistance of Breast Cancer. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.799428"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41419-023-05972-0","article-title":"HSPB1 Facilitates Chemoresistance through Inhibiting Ferroptotic Cancer Cell Death and Regulating NF-\u039aB Signaling Pathway in Breast Cancer","volume":"14","author":"Liang","year":"2023","journal-title":"Cell Death Dis."},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"Nedeljkovi\u0107, M., and Damjanovi\u0107, A. (2019). Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer\u2014How We Can Rise to the Challenge. Cells, 8.","DOI":"10.3390\/cells8090957"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1007\/s13577-023-00892-9","article-title":"Paraoxonase-2 Is Upregulated in Triple Negative Breast Cancer and Contributes to Tumor Progression and Chemoresistance","volume":"36","author":"Campagna","year":"2023","journal-title":"Hum. Cell"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13058-019-1150-z","article-title":"Nicotinamide N-Methyltransferase Enhances Chemoresistance in Breast Cancer through SIRT1 Protein Stabilization","volume":"21","author":"Wang","year":"2019","journal-title":"Breast Cancer Res."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1158\/0008-5472.CAN-23-0694","article-title":"The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4\/6 Inhibitor Resistance","volume":"83","author":"Lawson","year":"2023","journal-title":"Cancer Res."},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Crucitta, S., Ruglioni, M., Lorenzini, G., Bargagna, I., Luculli, G.I., Albanese, I., Bilancio, D., Patan\u00e8, F., Fontana, A., and Danesi, R. (2023). CDK4\/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients. Cancers, 15.","DOI":"10.3390\/cancers15041306"},{"key":"ref_205","first-page":"3067","article-title":"PI3K Inhibitors in Trastuzumab-Resistant HER2-Positive Breast Cancer Cells with PI3K Pathway Alterations","volume":"12","author":"Chung","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N. Eng. J. Med."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N. Eng. J. Med."},{"key":"ref_208","doi-asserted-by":"crossref","unstructured":"Liu, X., Wu, K., Zheng, D., Luo, C., Fan, Y., Zhong, X., and Zheng, H. (2021). Efficacy and Safety of PARP Inhibitors in Advanced or Metastatic Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.742139"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13046-021-01930-w","article-title":"Efficacy and Mechanism of the Combination of PARP and CDK4\/6 Inhibitors in the Treatment of Triple-Negative Breast Cancer","volume":"40","author":"Zhu","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S1470-2045(22)00284-4","article-title":"Fulvestrant plus Capivasertib versus Placebo after Relapse or Progression on an Aromatase Inhibitor in Metastatic, Oestrogen Receptor-Positive, HER2-Negative Breast Cancer (FAKTION): Overall Survival, Updated Progression-Free Survival, and Expanded Biomarker Analysis from a Randomised, Phase 2 Trial","volume":"23","author":"Howell","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"e076065","DOI":"10.1136\/bmj-2023-076065","article-title":"Pyrotinib versus Placebo in Combination with Trastuzumab and Docetaxel as First Line Treatment in Patients with HER2 Positive Metastatic Breast Cancer (PHILA): Randomised, Double Blind, Multicentre, Phase 3 Trial","volume":"383","author":"Ma","year":"2023","journal-title":"BMJ"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Eng. J. Med."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.annonc.2024.04.001","article-title":"IMpassion132 Double-Blind Randomised Phase III Trial of Chemotherapy with or without Atezolizumab for Early Relapsing Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer","volume":"35","author":"Dent","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"e05948","DOI":"10.1016\/j.heliyon.2021.e05948","article-title":"Drug Combination and Repurposing for Cancer Therapy: The Example of Breast Cancer","volume":"7","author":"Correia","year":"2021","journal-title":"Heliyon"},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Wang, Y., and Minden, A. (2022). Current Molecular Combination Therapies Used for the Treatment of Breast Cancer. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231911046"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.trecan.2017.09.001","article-title":"Breast Cancer: Multiple Subtypes within a Tumor?","volume":"3","author":"Yeo","year":"2018","journal-title":"Trends Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/7\/1102\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:00:09Z","timestamp":1760029209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/7\/1102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":216,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["cancers17071102"],"URL":"https:\/\/doi.org\/10.3390\/cancers17071102","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]}}}